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The acute-on-chronic liver failure (ACLF) is a syndrome characterized by liver
decompensation, hepatic encephalopathy (HE) and high mortality. We aimed to
determine the mechanisms implicated in the development of HE-associated cerebral
vasculopathy in a microsurgical liver cholestasis (MHC) model of ACLF. Microsurgical
liver cholestasis was induced by ligating and extracting the common bile duct
and four bile ducts. Sham-operated and MHC rats were maintained for eight
postoperative weeks Bradykinin-induced vasodilation was greater in middle cerebral
arteries from MHC rats. Both Nω-Nitro-L-arginine methyl ester and indomethacin
diminished bradykinin-induced vasodilation largely in arteries from MHC rats. Nitrite
and prostaglandin (PG) F1α releases were increased, whereas thromboxane (TX) B2
was not modified in arteries from MHC. Expressions of endothelial nitric oxide synthase
(eNOS), inducible NOS, and cyclooxygenase (COX) 2 were augmented, and neuronal
NOS (nNOS), COX-1, PGI2 synthase, and TXA2S were unmodified. Phosphorylation was
augmented for eNOS and unmodified for nNOS. Altogether, these endothelial alterations
might collaborate to increase brain blood flow in HE.
Keywords: acute-on-chronic liver failure, hepatic encephalopathy, cerebral vasculature, bradykinin, nitric oxide,
prostaglandin I2
INTRODUCTION
Liver cholestasis is a well-known clinical syndrome that may be induced by multiple pathologies
(Rodríguez-Garay, 2003). Independently of its origin, liver cholestasis is clinically characterized by
jaundice, discolored urine, pale stools, pruritus, spleen enlargement, liver cirrhosis, hepatorenal
syndrome, and portal hypertension, the latter due to an increase in portal vein resistance
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(Boyer, 2007). Alterations in endothelium-derived vasoactive
factors are determinant in the circulatory disturbances
observed in liver cholestasis, leading to the development
of portal hypertension and to a splanchnic and systemic
vasodilation (Pateron et al., 2000; Iwakiri and Groszmann,
2007). Different experimental models of liver cholestasis have
shown a decompensation after six postoperative weeks, together
with hepatic encephalopathy (HE) and ascites, leading to an
acute-on-chronic liver failure (ACLF; García-Moreno et al., 2005;
Gilsanz et al., 2017). This decompensation can aggravate these
cardiovascular disturbances, causing hypotension, decreased
effective blood volume, and increased cardiac output (Møller
et al., 2001; Sastre et al., 2016b; Caracuel et al., 2019), eventually
leading to patient death.
Hepatic encephalopathy is a complex neuropsychiatric
syndrome present in around 30% of the patients with ACLF
(Lizardi-Cervera et al., 2003). Although insufficient clearance
of toxins from blood, hyperammonemia, increased oxidative
stress and enhanced inflammatory pathways are pivotal in the
pathophysiology of HE, abnormalities in cerebral blood flow are
also implicated in the development of this syndrome (Shawcross
et al., 2004; Shawcross and Jalan, 2005). Both increases and
decreases in cerebral vasculature resistance have been reported
in HE, depending on the seriousness of the pathology, and
can lead to either a decrease or an increase in cerebral blood
flow, respectively (Guevara et al., 1998; Hollingsworth et al.,
2010; Sunil et al., 2012; Dam et al., 2013; Zheng et al., 2013).
In fact, an increased cerebral blood flow has been reported to
correlate with raised intracranial pressure in patients with ACLF
(Kerbert et al., 2017).
Several factors modulate physiological regulation of cerebral
blood flow, including neural, metabolic and endothelial factors.
Focusing on the last, endothelium exerts a profound influence on
blood flow in cerebral arteries by releasing nitric oxide (NO) and
prostanoids, among other factors (Andresen et al., 2006; Peterson
et al., 2011), thus regulating the tone of underlying smooth
muscle. Under inflammatory conditions, the role of vascular
endothelium can be modified in cerebral vessels (Hernanz et al.,
2004; Maccarrone et al., 2017), leading to increases in NO and
prostanoids release.
Despite the reports regarding modifications in cerebral blood
flow in HE, to the best of our knowledge the studies concerning
possible endothelial modifications in cerebral vasculature in
ACLF are scarce. Thus, the objective of this study was to
determine the mechanisms implicated in the development of
cerebral vasculopathy in microsurgical liver cholestasis (MHC), a
model of ACLF, which develops HE (García-Moreno et al., 2005;
Gilsanz et al., 2017). Specifically, we analyzed whether MHC
modifies the endothelial function in rat middle cerebral artery
(MCA), and the possible alterations of the endothelial vasoactive
factors in cerebral vasculature.
MATERIALS AND METHODS
Ethical Statements
All experimental procedures were approved by the Ethical
Committee of the Universidad Autónoma de Madrid, and the
Comunidad de Madrid (PROEX 322/16), are in compliance with
NIH guidelines, with the ARRIVE guidelines (Animal Research:
Reporting in Vivo Experiments) for how to REPORT animal
experiments, and follow the European Parliament Directive
2010/63/EU guidelines.
Animals
Thirty-four male Wistar rats (Initial weight: 337.9 ± 6.91 g)
were purchased from Harlan Ibérica SL, Barcelona, Spain and
housed in the Animal Facility of the Universidad Autónoma
de Madrid (Registration number EX-021U). Rats were held in
groups of 2 in appropriate cages in controlled environmental
conditions (20–24◦C, 55% relative humidity and 12 h light-dark
cycle). All rats had access to drinking water and specific rat chow
ad libitum.
Animals were randomly divided into two groups: Sham-
operated (SO; n = 17), in which the common bile duct was
dissected; and MHC (n = 17), in which the extrahepatic biliary
tract was resected (García-Moreno et al., 2005; Sastre et al.,
2016b; Gilsanz et al., 2017; Caracuel et al., 2019). Surgery
was performed under aseptic but not sterile conditions. In
summary, rats were anesthetized with Ketamine hydrochloride
(100 mg/kg) and xylazine (12 mg/kg) i.m. In the SO group,
the bile duct and its lobular branches were dissected. In
the MHC group, the extrahepatic bile tract was resected
using a binocular operatory microscope (Zeiss, OPMI 1-
FR). First, the common bile duct was ligated (silk 4/0)
and sectioned close to the beginning of its intrapancreatic
portion. Dissection and sectioning between ligatures of all
biliary branches that drain the hepatic lobes is possible using
a binocular operatory microscope (Zeiss, OPMI 1-FR). The
dissection and excision of the bile ducts from the four liver
lobes of the rat was done without injuring either the portal
and/or, most especially, the arterial vascularization of these
lobes. The abdomen was closed in two layers by continuous
running sutures using an absorbable suture (3/0 polyglycolic
acid) and silk (3/0). Buprenorphine s.c. (0.05 mg/kg/8 h)
was administered postoperatively for analgaesia the first 24 h
after the surgery.
Systolic Blood Pressure
Systolic blood pressure (SBP) was measured using the tail-cuff
method 8 weeks after the surgery was performed (Xavier et al.,
2010; Sastre et al., 2016b; Caracuel et al., 2019).
Portal Vein Pressure Measurement
After an overnight fasting, splenic pulp pressure, an indirect
measurement of portal pressure (PP) was measured in four
animals from each group, by inserting a fluid filled 20-gauge
needle into the splenic parenchyma (Sastre et al., 2016b;
Caracuel et al., 2019). The needle was joined to a PE-50
tube, and then connected to a pressure recorder (PowerLab
200 ML 201) and to a transducer (Sensonor SN-844) with a
Chart V 4.0 computer program (ADI Instruments), that was
calibrated before each experiment. The pressure reading was
considered satisfactory when a stable recording was produced
and respiratory variations were observed. Previous studies have
demonstrated the excellent correlation between splenic pulp
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pressure and PP (Kravetz et al., 1986). These animals were
discarded for the following experiments.
Animal Euthanasia and Sample
Collection
After an overnight fasting, animals were sacrificed by CO2
inhalation followed by decapitation. Ascitic liquid was carefully
extracted to measure its volume. Liver and spleen were extracted,
rinsed in saline solution and weighed. Kidneys were extracted,
rinsed in saline buffer, and frozen in liquid nitrogen and stored at
−70◦C, until use. Brain was removed and placed in cold Krebs–
Henseleit solution (KHS, in mmol/L: NaCl 115; CaCl2 2.5; KCl
4.6; KH2PO4 1.2; MgSO4·7H2O 1.2; NaHCO3 25; glucose 11.1,
Na2 EDTA 0.03) at 4◦C. Cerebral arteries were dissected under a
stereoscopic magnifying glass (Euromex Holland, Barcelona).
Gene Expression Studies
Total RNA was isolated from 1/4 rat renal samples with
TriPure Isolation Reagent (Sigma). cDNA was synthesized
using the NZY First-Strand cDNA Synthesis Kit (Nzytech)
using 2 µg of total RNA, following the manufacturer’s
instructions. Real Time PCR was performed in 7500 Fast
ABI System (Life Technologies Inc.) to detect gene expression
of Rat NGAL (FW: 5′-GAGCGATTCGTCAGCTTTGC-
3′; Rv:5′ATTGGTCGGTGGGAACAGAG-3′) and Rat
KIM-1 (FW:5′-AAGCCGAGCAAACATTAGTGC-3′; RV:5′-
TGAGCTAGAATTCAGCCACACA-3′). mRNA copy numbers
were calculated for each sample by the instrument software
using Ct value (“arithmetic fit point analysis for the lightcycler”).
Results are expressed in copy numbers, calculated relative to
control rat, after normalization with rat β2 microglobulin (Fw:
5′ ACCGTGATCTTTCTGGTGCTTG-3′; Rv: 5′ TAGCAGTTG
AGGAAGTTGGGCT-3′).
Vascular Reactivity Experiments
For vascular reactivity experiments, we used MCA segments
of 2 mm in length (internal diameter: SO: 231.4 ± 1.8 µm,
(n = 6); MHC: 233.8 ± 1.4 µm (n = 4); P > 0.05) were
mounted in a wire myograph for measurement of isometric
tension according to a described method (Hernanz et al., 2004).
Segment contractility was tested by an initial exposure to a
high-KCl solution (120 mmol/L KCl-KHS), observing a similar
vasoconstriction in MCA segments from both SO and MHC
animals (in mN/mm: SO: 2.216 ± 0.65; MHC: 2.194 ± 0.38;
P > 0.05).
Endothelium integrity was determined by the ability of
1 µmol/L bradykinin (BK) to relax segments precontracted with
10 µmol/L 5-hydroxytryptamine (5HT, serotonin). Afterward,
concentration-response curves for BK (0.1 nmol/L to 10 µmol/L)
were performed in 5HT-precontracted MCA segments from
SO and MHC rats. The effects of the non-selective NO
synthase inhibitor Nω -nitro-L-arginine methyl ester (L-
NAME, 0.1 mmol/L) or the non-specific cyclooxygenase (COX)
inhibitor indomethacin (10 µmol/L) on the concentration-
response curves for BK were investigated. The inhibitors
were added 30 min before the concentration-response curve
was performed. The inhibitors did not alter the arterial
basal tone.
The vasodilator response to the NO donor, diethylamine
NON-Oate, (DEA-NO, 0.1 nmol/L–0.1 mmol/L) was
determined in 5HT-precontracted MCA segments from
both experimental groups.
NADPH Oxidase Activity
The specific superoxide anion production generated by NADPH
oxidase activity was determined as previously described
(Llévenes et al., 2018). For that purpose, frozen cerebral
vasculature was homogenized in an ice-cold buffer containing
20 mmol/L KH2PO4, 1 mmol/L EGTA and 150 mmol/L
sucrose. The reaction was started by the addition of a lucigenin
(5 µmol/L)/NADPH (100 µmol/L) mixture to the tissue
homogenate. Chemiluminescence was determined every 2.4 s
for 5 min in a plate luminometer (AutoLumat LB 953, Berthold,
Germany). Buffer blank was subtracted from each reading.
Luminescence was normalized by protein concentration, and
data were expressed as chemiluminiscence units/µg protein.
Vasoactive Factor Production
The production of NO, TXA2 and PGI2 were measured using the
commercial kits Nitric Oxide Assay Kit (Abcam Laboratories),
Thromboxane (TX) B2 ELISA kit (Cayman Chemical) and 6-
keto Prostaglandin (PG) F1α ELISA Kit (Cayman Chemical),
respectively. For sample collecting, the cerebral vasculature was
pre-incubated for 30 min in 2 mL of KHS at 37◦C, continuously
gassed with a 95% O2–5% CO2 mixture (stabilization period).
This was followed by two washout periods of 10 min in a bath
of 0.2 mL of KHS. Then, the medium was collected to measure
basal release. Afterward, arteries were subjected to 10 µmol/L 5-
HT for 2 min, and then a BK concentration curve (0.1 nmol/L
to 10 µmol/L) was applied at 1 min intervals. Afterward, the
medium was collected to measure the BK-induced vasoactive
factor release. For NO production measurement, some samples
were collected in presence of 5 µmol/L L-NPA (specific neuronal
nitric oxide synthase – nNOS-inhibitor), 1 µmol 1400W (specific
inducible NOS – iNOS-inhibitor) or 0.1 mmol/L L-NAME. The
inhibitors were added 30 min before the concentration-response
curve to BK was performed. Samples were immediately frozen
in liquid nitrogen and conserved at −70◦C until the assays were
performed. The different assays were carried out according to the
manufacturers’ instructions.
Western Blot Analysis
For Western blot analysis, the cerebral vasculature were
homogenized in a buffer composed of 1 mmol/L sodium
vanadate (a protease inhibitor), 1% SDS, and 0.01 mol/L
pH 7.4 Tris–HCl. Protein content was determined using a
DCTM Protein Assay (Bio-Rad Laboratories, Hercules, CA,
United States). Homogenates containing 30 µg protein were
electrophoretically separated on a 7.5% (iNOS, eNOS, PS1177–
eNOS, nNOS, and PS1417 nNOS), or 10% (COX-1, COX-2,
TXA2 synthase, and PGI2 synthase) SDS–polyacrylamide gel
(SDS–PAGE), and then transferred to polyvinyl difluoride
membranes (Bio Rad Immun-Blot w) overnight at 4◦C,
230 mA, using a Bio-Rad Mini Protean Tetra system (Bio-
Rad Laboratories, Hercules, CA, United States) containing
25 mmol/L Tris, 190 mmol/L glycine, 20% methanol, and
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0.05% SDS. PageRuler Prestained Protein Ladder (Thermo
Scientific) was used as molecular mass markers. The
membranes were blocked for 3 h at room temperature
in a Tris-buffered-saline solution (100 mmol/L, 0.9% w/v
NaCl, 0.1% SDS) with 5% bovine serum albumin before
being incubated overnight at 4◦C with mouse monoclonal
anti-eNOS (1:1000, Transduction Laboratories), rabbit
polyclonal anti-PS1177 eNOS (1:1000, Abcam laboratories),
mouse monoclonal anti-nNOS (1:1000, Transduction
Laboratories), rabbit polyclonal anti-PS1417 nNOS (1:1000,
Abcam laboratories); mouse monoclonal anti-iNOS (1:1000,
Transduction Laboratories); rabbit monoclonal anti-COX-
1 (1:1000 dilution, Abcam laboratories); rabbit polyclonal
anti-COX-2 (1:2000 dilution, Cayman Chemical); rabbit
polyclonal anti-TXA2 synthase (1:500 dilution, Cayman
Chemical); or rabbit polyclonal anti-PGI2 synthase (1:500
dilution, Cayman Chemical). After washing, the membrane
was incubated with a 1:2000 dilution of the appropriate
secondary antibody (anti-mouse or anti-rabbit immunoglobulin
G antibody) conjugated to horseradish peroxidase (GE
Healthcare, Little Chalfont, United Kingdom). The membrane
was thoroughly washed and the immunocomplexes were
detected using an enhanced horseradish peroxidase/luminol
chemiluminescence system (ECL Plus, GE Healthcare,
Little Chalfont, United Kingdom). Finally, the images were
developed and quantified using the Quantity One software
(v. 4.6.6, Biorad, Spain). The same membranes were used
to determine β-actin expression (1:50000 dilution, Sigma-
Aldrich, Spain) and the content of the latter was used to correct
protein expression.
Drugs and Solutions
Drugs used were 5-hydroxytryptamine creatinine sulfate
(serotonin), bradykinin, sodium vanadate, L-NAME (Nω -
nitro-l-arginine methyl ester), indomethacin, SDS, Trizma-base
and bovine serum albumin (Sigma-Aldrich; Spain). Stock
solutions (10 mmol/L) were made in bidistilled water and kept at
−20◦C. Appropriate dilutions were made in KHS on the day of
the experiment.
Data Analysis
Graph representation and statistical analysis were performed
using GraphPad Prism 8.0 software (CA, United States). The
relaxations induced by BK were expressed as a percentage of
the initial contraction elicited by 5HT (in mN: SO: 1.18 + 0.15;
MHC: 1.29 + 0.19, P > 0.05). Non-lineal regressions were
performed. Areas under the curve (AUC) were calculated
from the individual concentration-response plots. Results were
expressed as mean ± standard error of the mean (SEM). In
vascular reactivity experiments, statistical analysis was performed
by means of two-way analysis of variance (ANOVA). For
differences of AUC (dAUC), vasoactive substance release and
Western blot experiments, the ROUT method was used to
identify and remove outliers. Moreover, a Shapiro–Wilk test
was applied to confirm the normality of the population data,




All MHC animals showed jaundice and choluria. Paraesophageal,
splenorenal and pararectal collateral vessels developed in MHC
animals (Data not shown). Final body weight and body weight
gain were lower in MHC animals. Systolic blood pressure was
lower, and PP was enhanced in the MHC group. Moreover,
both spleen and liver hypertrophy, and extravasation of ascitic
fluid were present in MHC animals (Table 1). We also found
that both neutrophil gelatinase-associated lipocalin (NGAL),
and Kidney injury molecule 1 (KIM-1), renal damage markers,
were enhanced after MHC (Table 2). In addition, a jaundice-
derived color and an inflammatory phenotype were found in rats
submitted to MHC (Figure 1). Altogether, these results confirm
that MHC is an appropriate experimental model for studying
hepatic and extrahepatic complications of this pathology.
Bradykinin-Induced Vasodilation
Large cerebral arteries, like MCA, strongly contribute to total
cerebrovascular resistance (Faraci and Heistad, 1990, 1998).
For that reason, we analyzed whether MHC could modify
the endothelium dependent BK-induced response in MCA.
We observed that BK produced a concentration-dependent
vasodilator response in MCA from both groups, which was
greater in MHC animals (Figure 2).
Role of Endothelium-Derived NO on the
Vasodilator Response to BK
One of the pivotal endothelial vasoactive factors modified by
inflammation is NO, which exerts a vasodilator effect in cerebral
vessels (Faraci and Heistad, 1998; Andresen et al., 2006). To
determine a different role of NO in SO and MHC animals,
we preincubated MCA segments with the non-selective NO
synthase inhibitor L-NAME. This drug diminished BK-induced
vasodilation in MCA segments from both groups, being this
decrease greater in arteries from rats submitted to MHCcerebral
vasculature from MHC (Figures 3A,B, and dAUC). It is also
remarkable that the vasodilator role to NO donor DEA-NO
was similar in MCA segments from both experimental groups
(Figure 3C). This result rules out possible differences in smooth
muscle sensitivity to NO in our experimental conditions.
To analyze whether this differential role of NO was due to
NO release, we analyzed the release of the stable NO metabolite
nitrite, finding that BK-induced nitrite release was greater in the
cerebral vasculature from MHC animals (Figure 4A).
Multiple enzymes are implicated in the NO synthesis.
When analyzing the influence of different NOS inhibitors in
nitrite release, we found that the specific nNOS inhibitor L-
NPA diminished BK-induced nitrite release in a similar extent
in cerebral vasculature from both experimental groups (in
percentage of inhibition: SO: 61.3 + 6.5; MHC: 65.1 + 3.1;
P > 0.05). In addition, the specific iNOS inhibitor 1400W
significantly decreased BK-induced nitrite release only in arteries
from MHC rats, while the non-specific NOS inhibitor L-NAME
abolished this release in the cerebral vasculature from both SO
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TABLE 1 | Effect of microsurgical liver cholestasis (MHC) on body weight (BW), body weight gain (BWG), systolic blood pressure (SBP), portal pressure (PP), liver weight
(LW), spleen weight (SW) and ascitic liquid extravasation in Wistar rats.
BW (g) BWG (g) SBP (mm Hg) PP (mm Hg) LW (g) SW (g) Ascitic liquid (mL)
SO 420.0 ± 9.98 77.12 ± 9.51 120.0 ± 3.67 8.49 ± 0.14 13.54 ± 0.51 0.74 ± 0.04 –
MHC 341.8 ± 12.42* 8.85 ± 5.28* 79.76 ± 3.31* 16.07 ± 1.38* 22.41 ± 1.73* 1.68 ± 0.12* 15.84 ± 5.69
Results are expressed as means ± SEM. *P < 0.05 versus SO (Student t-test). n = 4–17 animals each group.
TABLE 2 | NGAL and KIM-1 levels in kidneys from Sham-Operated (SO) and
microsurgical liver cholestasis (MHC) rats.
NGAL (n-fold) KIM-1 (n-fold)
SO 1 ± 0.21 1 ± 0.38
MHC 2.309 ± 0.67* 2.098 ± 0.52*
Results are expressed as means ± SEM. *P < 0.05 versus SO (Student t-test).
n = 6–9 animals each group.
and MHC rats (Figure 4A). We also observed an increase in iNOS
expression in arteries from MHC rats. Moreover, both eNOS
expression and phosphorylation in Ser 1177 were enhanced
in MHC cerebral arteries, while neither nNOS expression nor
Ser1417 phosphorylation were modified by MHC (Figure 4B).
Aside from NO release, it is also important to remark that
NO function also depends on its bioavailability. Liver pathologies
enhance oxidative stress in different tissues, including vascular
tissue (Xavier et al., 2010), thereby reducing NO function.
The fact that NADPH oxidase activity, the main producer of
superoxide anion, was similar in cerebral vasculature from both
experimental rules (Figure 4C), allowed us to rule out possible
alterations in NO bioavailability.
Role of COX-Derived Prostanoids on the
Vasodilator Response to BK
Modifications of other vasoactive factors could also be involved
in the pathogenesis of arterial vasodilation in MHC (Theodorakis
et al., 2003). To analyze the possible participation of prostanoids
in the enhanced BK-induced vasodilation observed in MHC
rats, we preincubated MCA with the unspecific COX inhibitor
indomethacin. We observed that BK-induced vasodilation was
not modified by indomethacin in MCA from SO animals, while it
was diminished in arteries from MHC rats (Figures 5A,B).
An overexpression of the enzymes implicated in prostanoid
synthesis has been reported in different vascular beds in rats with
FIGURE 1 | Representative pictures showing the brains from Sham-Operated (SO) and rats submitted to microsurgical liver cholestasis (MHC).
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FIGURE 2 | Effect of microsurgical liver cholestasis (MHC) on the
concentration-dependent relaxation to bradykinin in rat middle cerebral
arteries. Sham-Operated (SO): n = 6; MHC: n = 4. Results (mean ± SEM)
were expressed as a percentage of the initial contraction elicited by 5HT.
liver pathologies (Xavier et al., 2010). When analyzing COX-1,
we observed a similar expression in cerebral arteries from both
experimental groups, while the expression of COX-2 was greater
in cerebral arteries from MHC animals (Figure 6A).
Among the prostanoids implicated in the regulation of
vascular tone, both vasodilator PGI2 and vasoconstrictor TXA2
have a relevant role in cerebral vessels (Andresen et al., 2006;
Peterson et al., 2011; Maccarrone et al., 2017). When analyzing
the expressions of PGI2 synthase and TXA2 synthase, the
enzymes implicated in their synthesis, we observed no differences
among groups (Figure 6A). Moreover, when analyzing 6-keto
PGF1α and TXB2, the respective stable metabolites of PGI2 and
TXA2, we observed that MCH enhanced BK-induced 6-keto
PGF1α release but did not modify BK-induced TXB2 release
(Figures 6B,C).
DISCUSSION
The present study analyses the alterations in the cerebrovascular
function in rats submitted to MHC, a model of ACLF,
which develops HE. The results obtained show an enhanced
endothelium-dependent BK-induced vasodilation in MHC rats,
which is due to increases in the vasodilator factors NO and
PGI2 release.
Extrahepatic cholestasis is the most common model to study
the vascular complications of obstructive liver cholestasis. Rats
with MHC develop ACLF symptoms such as hepatomegaly, PH,
enlarged spleen, collateral portosystemic circulation, and ascites,
as reported earlier (Aller et al., 2012; Sastre et al., 2016b; Caracuel
et al., 2019). It is also remarkable that we previously described
alterations in albumin, total protein, bilirubin, and transaminases
after this experimental procedure (Gilsanz et al., 2017; Caracuel
et al., 2019). We can also highlight that these animals developed
hepatorenal syndrome, since both the renal damage markers
NGAL and KIM-1, were enhanced in kidneys from MHC rats.
In is also interesting to remark the jaundice-derived color and
the inflammatory phenotype that we observed in brains from
rats submitted to MHC. In addition, a previous study from our
group showed alterations in different brain structures, such as
the hippocampus, several weeks after this surgery was performed
(García-Moreno et al., 2002). These alterations were accentuated
after 8 weeks of the surgery (Braissant et al., 2019), consequently
developing behavioral changes including both cognitive and
motor impairment, which worsen together with the severity of
the pathology (García-Moreno et al., 2002; Giménez-Garzó et al.,
2015; Braissant et al., 2019). Altogether, these data allow us to
confirm that MHC is an appropriate experimental model for
studying hepatic and extrahepatic complications, including HE
alterations, developed in ACLF.
Microsurgical liver cholestasis is characterized by the
development of systemic vascular complications, which can be
the origin of the HE associated to ACLF (Jalan and Williams,
2002; Wright et al., 2014). Moreover, previous studies have
reported that a systemic proinflammatory state can activate
microglia and consequently produce a neuroinflammatory
situation, therefore worsening the neuropsychiatric symptoms of
HE (Butterworth, 2013; Rama Rao et al., 2014; Macías-Rodríguez
et al., 2015). This proinflammatory state can modify the release of
endothelial vasoactive factors in several vascular beds, including
cerebral vessels (Faraci and Heistad, 1998; Andresen et al.,
2006), consequently altering cerebral blood flow and vascular
resistance, and contributing to the development of the brain
abnormalities observed in this pathology. Large cerebral arteries,
like MCA, strongly contribute to total cerebrovascular resistance,
being the main determinants of local microvascular pressure
(Faraci and Heistad, 1990, 1998). For that reason, we analyzed
whether MHC could modify the endothelium dependent BK-
induced response in MCA. We observed an augmented BK
vasodilation in vessels from MHC rats, as has been reported
in other vascular beds (Xavier et al., 2010; Hollenberg and
Waldman, 2016; Caracuel et al., 2019). As we commented in the
introduction section, alterations in the balance of vasodilator and
vasoconstrictor agents are frequent in liver pathologies, leading
to blood flow alterations in multiple vascular beds (Xavier et al.,
2010; Bolognesi et al., 2014; Bosch et al., 2015; Sastre et al.,
2016b; Caracuel et al., 2019). One of the pivotal endothelial
vasoactive factors modified by inflammation is NO, which exerts
a vasodilator effect in cerebral vessels both in vivo and ex vivo by
activating soluble guanylate cyclase and/or producing smooth
muscle hyperpolarization through potassium channel opening
(Faraci and Heistad, 1998; Andresen et al., 2006). A dysregulation
of NO production is a common denominator of most of the
symptoms accompanying liver pathologies. The role of NO is
reported to vary in different vascular beds. Thus, a decrease
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FIGURE 3 | Effect of preincubation with NOS inhibitor L-NAME on the concentration-dependent relaxation to bradykinin in rat middle cerebral arteries from
Sham-Operated (SO), (A); (n = 4–6 segments from different animals) and microsurgical liver cholestasic (MHC), (B); (n = 4 segments from different animals) rats.
Results (mean ± SEM) were expressed as a percentage of the initial contraction elicited by 5HT. The attached graph shows the differences of area under the curve
(dAUC) to bradykinin for segments in the absence or presence of 0.1 mmol/L L-NAME. dAUC values are expressed as a percentage of the difference of the
corresponding AUC for the segments in the absence of L-NAME. (C) Vasodilator response to NO donor DEA-NO in arteries from SO and MHC rats (n = 4 segments
from different animals in each group). Results (mean ± SEM) were expressed as a percentage of the initial contraction elicited by 5HT.
in NO levels has been described in portal vein, increasing the
resistance in this vascular bed. Conversely, increases in NO have
also been reported in systemic vasculature and plasma, where
they participate in the development of hyperdynamic circulation
in splanchnic and systemic circulation (Bolognesi et al., 2014;
Bosch et al., 2015; Hollenberg and Waldman, 2016). We
observed that, similar to earlier reports in different splanchnic
and systemic vascular beds (Xavier et al., 2010; Sastre et al.,
2016b; Caracuel et al., 2019), BK-induced nitrite (the stable NO
metabolite) levels were significantly increased in cerebral arteries
from MHC rats compared to SO animals. This result correlates
with the fact that preincubation with unspecific NOS inhibitor
L-NAME diminished BK-induced relaxation to a greater extent
in MCA from MHC rats, hence confirming a major functional
role for NO in this experimental group. In addition, the fact that
the vasodilator role to NO donor DEA-NO was similar in MCA
segments from both experimental groups allowed us to rule out
possible differences in both smooth muscle sensitivity to NO and
in the NO signaling pathway in MCA due to MHC.
NO can be synthetized through the action of both constitutive
eNOS and nNOS, and inducible iNOS. The increase in iNOS
expression in splanchnic vasculature suggests involvement
by iNOS-derived NO in the development of hyperdynamic
circulation in different liver pathologies (Bhimani et al.,
2003; Ferguson et al., 2006; Xavier et al., 2010). Given the
fact that iNOS plays a relevant role in NO synthesis in
brain under inflammatory conditions (Hernanz et al., 2004;
Rama Rao et al., 2014), we analyzed possible differences in
iNOS expression under our experimental conditions, finding an
increase in this enzyme expression in cerebral arteries from MHC
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FIGURE 4 | (A) Bradykinin-induced nitrite release in cerebral vasculature from Sham-Operated (SO; n = 4-9 animals) and microsurgical liver cholestasic (MHC;
n = 4–10 animals) rats. Effect of preincubation with specific nNOS inhibitor L-NPA, specific iNOS inhibitor 1400W, or non-specific NOS inhibitor L-NAME. Data
(Mean ± SEM) were expressed as nmol nitrites/mg tissue. *P < 0.05 SO vs MHC (Student t-test). #P < 0.05 conditions without drug vs. conditiosmn with drug
(Student t-test). (B) Western blot analysis for and inducible nitric oxide synthase (iNOS), total and phosphorylated endothelial nitric oxide synthase (eNOS) in the Ser
1177 residue (P-eNOS), and total and phosphorylated neuronal nitric oxide synthase (nNOS) in the Ser 1417 residue (P-nNOS), in cerebral arteries from
Sham-Operated (SO) and microsurgical liver cholestasis (MHC) rats. The blots are representative of 4–7 segments from each group. Lower panels show
densitometry analysis for the expression of each protein. Results (mean ± SEM) were expressed as the relation between the signal obtained for the protein analyzed
and the signal obtained for β-actin. *P < 0.05 SO vs MHC (Student t test). (C) NADPH activity in cerebral vessels from SO and MHC rats (n = 5 different animals from
each group). Results (mean ± SEM) were expressed as chemiluminiscence units (CU.)/µg protein.
animals. Consequently, the increase in iNOS expression in MHC
animals would explain the augmented NO release observed in
this experimental group. The fact that the specific iNOS inhibitor
1400W reduced nitrite release only in cerebral vessels from MHC
rats corroborates this hypothesis, thereby confirming the relevant
role of iNOS in the vascular alterations in MHC.
We must also take into account that both constitutive isoforms
eNOS and nNOS are also present in vascular endothelium of
cerebral arteries (Andresen et al., 2006; Iwakiri and Groszmann,
2007). An increase in eNOS expression was described in the
splanchnic and systemic vascular beds in several liver pathology
models (Wright et al., 2012; Lin et al., 2014), and eNOS-
derived NO has been described to be high in cerebral vessels
under inflammatory status (Ando et al., 2004; Maccarrone
et al., 2017). Thus, we cannot rule out possible alterations
in eNOS expression/activation in cerebral arteries from MHC
animals. An increase in eNOS expression was found in cerebral
vessels from MHC rats. Additionally, we observed an augmented
eNOS phosphorylation at Ser1177, indicating enhanced eNOS
activation, as we previously described in mesenteric vascular bed
(Xavier et al., 2010; Caracuel et al., 2019).
Regarding nNOS-derived NO, it is implicated in the increased
vasodilation observed in splanchnic and systemic vasculature
in liver pathologies, including ACLF (Xu et al., 2000; Sastre
et al., 2016b), while several reports have described that nNOS
is present in cultured endothelial cells from different vascular
beds, exerting an anti-inflammatory role (Chakrabarti et al.,
2012). We found no modifications in either nNOS expression
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FIGURE 5 | Effect of preincubation with COX inhibitor indomethacin on the concentration-dependent relaxation to bradykinin in rat middle cerebral arteries from
Sham-Operated (SO), (A); (n = 4–6 segments from different animals) and microsurgical liver cholestasic (MHC), (B); (n = 4 segments from different animals) rats.
Results (mean ± SEM) were expressed as a percentage of the initial contraction elicited by 5HT.
or phosphorylation on Ser1417. Moreover, the specific inhibition
of nNOS diminished NO release in a similar extent in both
experimental groups. These results contrast with these studies
previously mentioned. The different tissues and experimental
model could explain this discrepancy. Altogether, these results
show that the observed increase in NO release in cerebral
arteries from MHC rats could be due to augmented eNOS and
iNOS activity.
Multiple studies have shown that MHC induced a systemic
increase of oxidative stress. Specially, enhanced pro-oxidative
biomarkers and diminished antioxidant mechanisms have been
reported in brain from MHC rats (Ommati et al., 2020). In
blood vessels, superoxide anions can modulate the role of
NO, diminishing its bioavailability. Although there are several
sources of reactive oxygen species, the enzyme NADPH oxidase
is the main producer of the excessive superoxide anions
in vascular tissue (Miller et al., 2010; Sastre et al., 2016a;
Llévenes et al., 2018). When analyzing the activity of this
enzyme, we found no differences between our experimental
groups. This result might contrast with the fact that liver
pathologies enhance vascular oxidative stress in other vascular
beds (Xavier et al., 2010), while we also found no differences
in superoxide anions in superior mesenteric artery from MHC
rats (unpublished results from our group). It is interesting to
remark that an enhanced systemic oxidative stress systemic
does not necessary correlate with local alterations in superoxide
anions (Torres et al., 2019; Llévenes et al., 2020). In addition,
we cannot rule out the participation of other sources of
vascular superoxide anions. Since the functional analysis
of NO-induced vasodilation showed no differences between
SO and MHC rats, we can infer that the oxidative stress
participation in cerebral vasculature might not change due
to MHC.
Aside from excess NO generation in the splanchnic
circulation, data from eNOS and iNOS knockout mice suggests
that modifications of vasoactive factors other than NO could
be involved in the pathogenesis of arterial vasodilation in liver
pathologies (Theodorakis et al., 2003). Endothelial prostanoids,
synthetized through COX activation, participate in the regulation
of vascular tone in healthy situations, depending on the vascular
bed analyzed, but their production can be modified under
certain inflammatory pathological situations (Brian et al.,
2001; Hernanz et al., 2004; Mollace et al., 2005; Blanco-Rivero
et al., 2007; Peterson et al., 2011; Wiggers et al., 2016). In fact,
multiple studies have already focused on the role of COX-derived
vasodilator (PGI2) and vasoconstrictor (TXA2) prostanoids in
the vascular disturbances observed in liver pathologies (Xavier
et al., 2010; Macías-Rodríguez et al., 2015; Caracuel et al., 2019).
Therefore, we aimed to determine the possible differential
influence of prostanoids on the BK-induced vasodilation in
cerebral vessels from SO and MHC rats. For that purpose, we
incubated MCA segments with the non-specific COX inhibitor
indomethacin, observing that this drug exerted no influence in
vessels from SO animals, as previously described (Wiggers et al.,
2016), while it diminished BK-induced vasodilation in arteries
from MHC animals. Previously, an overexpression of COX-2 was
described in splanchnic vasculature in liver pathologies (Xavier
et al., 2010). What is more, alterations in constitutive COX-1
expression have also been reported in several tissues, including
endothelium and brain tissue (Zheng et al., 2013; Kerbert et al.,
2017). Therefore, we aimed to investigate possible alterations in
the expression of both COX isoforms. We found a greater COX-2
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FIGURE 6 | (A) Western blot analysis for cyclooxygenase (COX) 1 and 2, PGI2 synthase (PGI2S) and TXA2 synthase (TXA2S) in cerebral arteries from
Sham-Operated (SO) and microsurgical liver cholestasis (MHC) rats. The blots are representative of 6–7 segments from each group. Lower panels show
densitometry analysis for the expression of each protein. Results (mean + SEM) were expressed as the relation between the signal obtained for the protein analyzed
and the signal obtained for β-actin. *P < 0.05 SO vs MHC (Student t-test). Effect of microsurgical liver cholestasis (MHC) on cerebral artery 6-Keto PGF1α release
(B); (SO: n = 9 animals; MHC: n = 10 animals) and TXB2 release (C); (n = 10 animals from each experimental group) Results (mean ± SEM) were expressed as pg
prostanoid/mL mg tissue. *P < 0.05 SO vs MHC (Student t-test).
expression in cerebral arteries from MHC rats, while COX-1
was not modified in our experimental conditions. Therefore, the
increase in COX-2 expression we observed in cerebral arteries
suggests the presence of alterations in prostanoid release in
this vascular bed.
One of the main vasodilator prostanoid present in cerebral
arteries is PGI (Andresen et al., 2006; Xavier et al., 2010; Peterson
et al., 2011; Maccarrone et al., 2017). We observed an increase
in BK-induced 6-keto PGF1 α (the stable PGI2 metabolite)
release in cerebral arteries from MHC animals, similarly to
that reported in aorta and mesenteric resistance arteries in
diverse liver pathologies (González-Correa et al., 1996; Blanco-
Rivero et al., 2009; Xavier et al., 2010). Since no differences
in PGI2 synthase expression were observed, we could attribute
the increased PGI2 release in MHC cerebral arteries to the
augmented COX-2 expression, but we cannot exclude a possible
enhancement in PGI2S activity.
Aside from vasodilator PGI2, COX-derived vasoconstrictor
TXA2 also has a relevant role in the regulation of vascular tone in
cerebral arteries (Hou et al., 2000; Andresen et al., 2006; Peterson
et al., 2011). In fact, inter-relations between both prostanoids
have been described (Cheng et al., 2002; Mollace et al., 2005).
Modifications in TXA2 participation have been described in
cerebral vasculature in different pathologies (Andresen et al.,
2006). Regarding liver pathologies, both increases and decreases
in TXA2 participation have been described in portal vein and
splanchnic vasculature, respectively (Iwakiri and Groszmann,
2007; Gatta et al., 2008; Xavier et al., 2010), but, to the best of
our knowledge, no reports regarding possible modifications in
this vasoconstrictor factor have been observed in cerebral vessels.
When measuring the stable TXA2 metabolite, TXB2, we found
no differences between its release in cerebral arteries from SO
and MHC rats, agreeing with the observation that TXA2 synthase
expression was similar in both experimental groups. Altogether,
these data show augmented PGI2 release in cerebral arteries from
MHC rats, mainly due to the increase in COX-2 expression, while
no modification in TXA2 release was observed.
An extravasation of ascitic fluid to the abdominal cavity is
found in this MHC model after a six-week evolution of the
pathology, being this symptom characteristic of ACLF. Regarding
cerebral vasculature, the vasculopathy that we observed in the
present study could be implicated in the development of HE
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related to an ACLF, characterized by a brain edema and
hypoxia situation, which might consequently lead to CNS
ischemia (Faraci and Heistad, 1990; Theodorakis et al., 2003;
Sawhney et al., 2016). In fact, after a longer evolution of MHC
(8 weeks or more), the animals die after going into a coma.
Therefore, it would be interesting in the future to determine the
pathogenic influence of vasoactive mediators in the development
of the endothelial permeability that causes the HE related
to ACLF.
In conclusion, we observed an enhanced BK-induced
vasodilation observed in MCA from MHC rats, due to increased
NO and PGI2. This augmented vasodilation might collaborate to
increase brain blood flow in HE, and consequently be implicated
in the brain alterations observed in ACLF.
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